Today: 27 December 2025
Subscribe

MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

MSP Recovery (MSPR) Stock Jumps Over 20% Pre‑Market as Q3 Delay and Nasdaq Fight Keep Volatility High – 17 November 2025

Important: This article is news and analysis, not investment advice. MSPR is a highly speculative micro‑cap; anyone considering it should do independent research and consider professional guidance. What’s Happening With MSPR Today (17 November 2025)? Pre‑market spike puts MSPR back
17 November 2025
·····
Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Saab AB (SAAB-B.ST) Jumps on €3.1bn Gripen Colombia Deal as New Drone and Solar Partnerships Emerge – 17 November 2025

Swedish defence and security group Saab AB (publ) (B‑share ticker SAAB‑B.ST) is firmly in the spotlight today after a wave of fighter‑jet contracts, electronic‑warfare orders and new technology partnerships pushed the stock sharply higher and sparked fresh debate about valuation
17 November 2025
····
Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition: Price, Features, Release Date and Why It’s the New Go‑To Controller for Xbox Cloud Gaming (November 17, 2025)

Backbone Pro Xbox Edition is the latest “Designed for Xbox” mobile controller, blending full-size gamepad comfort with cross‑device Xbox Cloud Gaming support. Here’s everything you need to know today, November 17, 2025 – price, specs, compatibility, and early reactions. What
17 November 2025
·····
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in
17 November 2025
····
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on
17 November 2025
········
1 … 977 978 979 980 981 … 1,536
Go toTop